Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 4Neoplasm Metastasis 3Colorectal Neoplasms 2Central Nervous System Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Small Cell Lung Carcinoma 1Rhabdomyosarcoma 1Ovarian Neoplasms 1Microphthalmia, Isolated, with Coloboma 5 1Medulloblastoma 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Head and Neck Neoplasms 1Fanconi Anemia 1Desmoplastic Small Round Cell Tumor 1Carcinoma, Squamous Cell 1Breast Neoplasms 1Brain Neoplasms 1Anus Neoplasms 1Advanced Cancer 1

Interventions

Nivolumab 13Surveys and Questionnaires 6Ipilimumab 6linrodostat 5Standard of Care 5Paclitaxel 5Bevacizumab 5Sirolimus 4Pemetrexed 4Interviews as Topic 4Gemcitabine 4Docetaxel 4ARRY-334543 4temsirolimus 3relatlimab 3Erlotinib Hydrochloride 3Cetuximab 3Carboplatin 3regorafenib 2anlotinib 2abemaciclib 2Vorinostat 2Trastuzumab 2Sorafenib 2N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide 2Magnetic Resonance Spectroscopy 2Doxorubicin 2Dasatinib 2Cyclophosphamide 2vorolanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Advanced Cancer × prexasertib × Clear all
NCT02778126 2019-08-01

A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer

Eli Lilly and Company

Phase 1 Completed
6 enrolled

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡